Literature DB >> 12456770

Angiogenesis in epithelian ovarian cancer.

E S Bamberger1, C W Perrett.   

Abstract

Angiogenesis, the development of new blood vessels from the existing vasculature, is an essential component of solid tumour growth and metastasis. Several angiogenic factors are expressed by many tumours, suggesting that tumours promote their own vascularisation by activating the host endothelium. This review will discuss various angiogenic stimulators and inhibitors in epithelian ovarian cancer (EOC), including vascular endothelial growth factor and platelet derived endothelial cell growth factor/thymidine phosphorylase. The analysis of tumour vascularisation by microvessel density will also be discussed and the relevance of these markers of angiogenesis in the prognosis of EOC will be assessed.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12456770      PMCID： PMC1187269          DOI： 10.1136/mp.55.6.348

Source DB:  PubMed          Journal:  Mol Pathol        ISSN： 1366-8714


  164 in total

Review 1.  Ovarian cancer biology.

Authors:  R P Perez; A K Godwin; T C Hamilton; R F Ozols
Journal:  Semin Oncol       Date:  1991-06       Impact factor: 4.929

2.  The association between tumour progression and vascularity in the oral mucosa.

Authors:  S Pazouki; D M Chisholm; M M Adi; G Carmichael; M Farquharson; G R Ogden; S L Schor; A M Schor
Journal:  J Pathol       Date:  1997-09       Impact factor: 7.996

Review 3.  Pathology of epithelial ovarian tumors.

Authors:  H Krigman; R Bentley; S J Robboy
Journal:  Clin Obstet Gynecol       Date:  1994-06       Impact factor: 2.190

4.  Dramatic inhibition of retinal and choroidal neovascularization by oral administration of a kinase inhibitor.

Authors:  M S Seo; N Kwak; H Ozaki; H Yamada; N Okamoto; E Yamada; D Fabbro; F Hofmann; J M Wood; P A Campochiaro
Journal:  Am J Pathol       Date:  1999-06       Impact factor: 4.307

5.  Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal.

Authors:  L E Benjamin; E Keshet
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

6.  Role of angiogenesis in benign, premalignant and malignant vulvar lesions.

Authors:  A B MacLean; W M Reid; K J Rolfe; S J Gammell; H E Pugh; K C Gatter; A C Wong Te Fong; J C Crow; C W Perrett
Journal:  J Reprod Med       Date:  2000-08       Impact factor: 0.142

7.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

8.  A potent inhibitor of endothelial cell proliferation is generated by proteolytic cleavage of the chemokine platelet factor 4.

Authors:  S K Gupta; T Hassel; J P Singh
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Platelet-derived endothelial cell growth factor/thymidine phosphorylase expression in normal tissues: an immunohistochemical study.

Authors:  S B Fox; A Moghaddam; M Westwood; H Turley; R Bicknell; K C Gatter; A L Harris
Journal:  J Pathol       Date:  1995-06       Impact factor: 7.996

10.  Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions.

Authors:  K T Yeo; H H Wang; J A Nagy; T M Sioussat; S R Ledbetter; A J Hoogewerf; Y Zhou; E M Masse; D R Senger; H F Dvorak
Journal:  Cancer Res       Date:  1993-06-15       Impact factor: 12.701
View more
  51 in total

1.  The role of dysregulated glucose metabolism in epithelial ovarian cancer.

Authors:  L D Kellenberger; J E Bruin; J Greenaway; N E Campbell; R A Moorehead; A C Holloway; J Petrik
Journal:  J Oncol       Date:  2010-02-17       Impact factor: 4.375

2.  Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.

Authors:  Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Ken-Yu Lin; Marta Bellone; Paola Todeschini; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Luisa Carrara; Renata Tassi; Sergio Pecorelli; Charles J Lockwood; Alessandro D Santin
Journal:  Clin Exp Metastasis       Date:  2011-07-02       Impact factor: 5.150

3.  Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.

Authors:  Minghai Shao; Stacy Hollar; Daphne Chambliss; Jordan Schmitt; Robert Emerson; Bhadrani Chelladurai; Susan Perkins; Mircea Ivan; Daniela Matei
Journal:  Mol Cancer Ther       Date:  2012-06-13       Impact factor: 6.261

Review 4.  Assessing the effects of threonyl-tRNA synthetase on angiogenesis-related responses.

Authors:  Adam C Mirando; Khadar Abdi; Peibin Wo; Karen M Lounsbury
Journal:  Methods       Date:  2016-11-12       Impact factor: 3.608

5.  Contrast-enhanced sonography depicts spontaneous ovarian cancer at early stages in a preclinical animal model.

Authors:  Animesh Barua; Pincas Bitterman; Janice M Bahr; Sanjib Basu; Eyal Sheiner; Michael J Bradaric; Dale B Hales; Judith L Luborsky; Jacques S Abramowicz
Journal:  J Ultrasound Med       Date:  2011-03       Impact factor: 2.153

Review 6.  Following up tumour angiogenesis: from the basic laboratory to the clinic.

Authors:  José L Orgaz; Beatriz Martínez-Poveda; Nuria I Fernández-García; Benilde Jiménez
Journal:  Clin Transl Oncol       Date:  2008-08       Impact factor: 3.405

7.  Sp-1 and c-Myc mediate lysophosphatidic acid-induced expression of vascular endothelial growth factor in ovarian cancer cells via a hypoxia-inducible factor-1-independent mechanism.

Authors:  Yuanda Song; Jinhua Wu; Regina A Oyesanya; Zendra Lee; Abir Mukherjee; Xianjun Fang
Journal:  Clin Cancer Res       Date:  2009-01-15       Impact factor: 12.531

Review 8.  Current status of anti-angiogenic agents in the treatment of ovarian carcinoma.

Authors:  Alfonso Sánchez-Muñoz; Elisabeth Pérez-Ruiz; César Mendiola Fernández; Emilio Alba Conejo; Antonio González-Martín
Journal:  Clin Transl Oncol       Date:  2009-09       Impact factor: 3.405

9.  Second complete remission induced by cyclophosphamide plus bevacizumab in two patients with heavily pre-treated ovarian cancer.

Authors:  A Sánchez-Muñoz; J M Jurado; E Pérez-Ruiz; E Alba
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

10.  A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Hatem Elalfy; Tarek Fouad Sheta; Mahmoud Awad; Mostafa Abdelsalam; Rania Elhelaly; Rasha Elzehery; Nawal S Gouda; Waleed Eldars
Journal:  J Gastrointest Cancer       Date:  2017-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.